118 related articles for article (PubMed ID: 38072718)
1. Quantitative Parameters of Contrast-Enhanced Ultrasound Predicting the Response to Combined Immune Checkpoint Inhibitor and Anti-angiogenesis Therapies for Unresectable Hepatocellular Carcinoma.
Zhang Y; Zheng R; Liu M; Zhang X; Sun Y; Shen H; Chen S; Cai H; Guo W; Xie X; Liu B; Huang G
Ultrasound Med Biol; 2024 Mar; 50(3):352-357. PubMed ID: 38072718
[TBL] [Abstract][Full Text] [Related]
2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
3. Potential application of dynamic contrast enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma.
Dong Y; Qiu Y; Yang D; Yu L; Zuo D; Zhang Q; Tian X; Wang WP; Jung EM
Clin Hemorheol Microcirc; 2021; 77(4):461-469. PubMed ID: 33459703
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
5. Applications of Dynamic Contrast-Enhanced Ultrasound in Differential Diagnosis of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in Non-cirrhotic Liver.
Dong Y; Chen S; Möller K; Qiu YJ; Lu XY; Zhang Q; Dietrich CF; Wang WP
Ultrasound Med Biol; 2023 Aug; 49(8):1780-1788. PubMed ID: 37156676
[TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment.
Feng Y; Zhang H; Ren Q; Li C; Liu S; Zheng C; Xia X
Eur J Radiol; 2023 May; 162():110784. PubMed ID: 36958125
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation.
Gao Y; Zheng DY; Cui Z; Ma Y; Liu YZ; Zhang W
World J Gastroenterol; 2015 Sep; 21(36):10418-26. PubMed ID: 26420968
[TBL] [Abstract][Full Text] [Related]
8. Quantitative perfusion analysis of hepatocellular carcinoma using dynamic contrast enhanced ultrasound (CEUS) to determine tumor microvascularization.
Schaible J; Stroszczynski C; Beyer LP; Jung EM
Clin Hemorheol Microcirc; 2019; 73(1):95-104. PubMed ID: 31561349
[TBL] [Abstract][Full Text] [Related]
9. HCC treated with immune checkpoint inhibitors: a hyper-enhanced rim on Sonazoid-CEUS Kupffer phase images is a predictor of tumor response.
Huang Z; Zhu RH; Xin JY; Li KY
Eur Radiol; 2023 Jun; 33(6):4389-4400. PubMed ID: 36547674
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Conventional Ultrasound and Contrast-Enhanced Ultrasound in Early Recurrence of Hepatocellular Carcinoma after Surgical Resection.
Wang Y; Liao J; Qi W; Xie L; Li Y
Ultrasound Med Biol; 2016 May; 42(5):1042-8. PubMed ID: 26803390
[TBL] [Abstract][Full Text] [Related]
11. Savitzky-Golay filter based contrast-enhanced ultrasound quantification in hepatic tumors: Methodology and its correlation with tumor angiogenesis.
Peng S; Ding H; Fu T; Wang B; Wang W; Zhou J
Clin Hemorheol Microcirc; 2019; 73(2):271-282. PubMed ID: 30103307
[TBL] [Abstract][Full Text] [Related]
12. The value of contrast-enhanced ultrasound quantitative parameters in the prognosis prediction of hepatocellular carcinoma after thermal ablation: a retrospective cohort study.
Gu DY; Zhang Y; Hu JX; Qin HY; Lu X; He GB; Shang L
J Gastrointest Oncol; 2022 Oct; 13(5):2522-2531. PubMed ID: 36388675
[TBL] [Abstract][Full Text] [Related]
13. Value of Perfusion Parameters for Differentiating Hepatocellular Carcinoma and Liver Metastasis With Hypervascularity and a Normal Hepatic Background on Contrast-Enhanced Ultrasound Imaging.
Lu Q; Zhang XL; Han H; Huang BJ; Ding H; Wang WP
J Ultrasound Med; 2019 Oct; 38(10):2601-2608. PubMed ID: 30697787
[TBL] [Abstract][Full Text] [Related]
14. Contrast-Enhanced Ultrasound Findings and Differential Diagnosis of Hepatic Epithelioid Angiomyolipoma Compared with Hepatocellular Carcinoma.
Huang Z; Wu X; Li S; Li K
Ultrasound Med Biol; 2020 Jun; 46(6):1403-1411. PubMed ID: 32165015
[TBL] [Abstract][Full Text] [Related]
15. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
16. Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound.
Cao J; Dong Y; Fan P; Mao F; Chen K; Chen R; Huang B; Cheng Y; Wang WP
Clin Hemorheol Microcirc; 2021; 78(4):365-377. PubMed ID: 33682701
[TBL] [Abstract][Full Text] [Related]
17. Comparison of volume perfusion computed tomography and contrast-enhanced ultrasound for assessment of therapeutic effect of transarterial chemoembolization in patients with hepatocellular carcinoma: a preliminary report.
Kaufmann S; Schulze M; Spira D; Horger M
Acta Radiol; 2016 Jan; 57(1):8-12. PubMed ID: 25585848
[TBL] [Abstract][Full Text] [Related]
18. Role of portal vein tumor thrombosis in quantitative perfusion analysis of contrast-enhanced ultrasound of hepatocellular carcinoma.
Wang Z; Liu G; Lu MD; Xie X; Kuang M; Wang W; Xu Z; Lin M; Chen L
Ultrasound Med Biol; 2015 May; 41(5):1277-86. PubMed ID: 25623820
[TBL] [Abstract][Full Text] [Related]
19. Parametric imaging with contrast-enhanced ultrasound for differentiating hepatocellular carcinoma from metastatic liver cancer.
Yue WW; Wang S; Xu HX; Sun LP; Guo LH; Bo XW; Li XL; Zhao CK; Wang D; Liu BJ
Clin Hemorheol Microcirc; 2016 Nov; 64(2):177-188. PubMed ID: 27258196
[TBL] [Abstract][Full Text] [Related]
20. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
Knieling F; Waldner MJ; Goertz RS; Zopf S; Wildner D; Neurath MF; Bernatik T; Strobel D
Ultraschall Med; 2013 Feb; 34(1):38-46. PubMed ID: 23258770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
